The average 12-month price target for Biomarin Pharmaceutical has decreased by 4.69% from the previous average, indicating a mixed sentiment among analysts. While the stock has both bullish and bearish ratings, the overall impact on the stock price in the short term is neutral as the change in the average price target is not significant enough to cause a strong price movement.